Business
ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
-- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board -- SAN CARLOS, Calif., July 05, 2022
About this update from Chemocentryx Inc.
[{"type":"text","content":"-- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board --\nSAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. “With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Jennifer’s values closely align with our organization, and we are confident this addition benefits patients, caregivers, and shareholders alike as we continue to grow and bring TAVNEOS to appropriate patients in need.” Ms. Herron serves as Senior Vice President and Chief Commercial Officer of ADC Therapeutics, which she joined in November 2019 to build its commercial organization and launch its first marketed product. Before ADC Therapeutics, she was Executive Vice President and Chief Commercial Officer at Immunogen and President and Executive Vice President, Global Commercial, at MorphoSys US. In 2016 and 2017, Ms. Herron led the Commercial organization at Ariad Pharmaceuticals as Executive Vice President and Chief Commercial Officer and prepared the organization to launch its second commercial product. Earlier in her career, she held commercial leadership roles of increasing responsibility with Bristol-Myers Squibb, Novartis Oncology, and SmithKline Beecham Oncology (GlaxoSmithKline). Ms. Herron holds an MBA from Georgetown University and a BA in Biology and Economics from Lehigh University. “TAVNEOS is truly a unique medicine with potential to improve the lives of many patients that have been underserved for far too long,” said Ms. Herron. “I look forward to bringing my experience to ChemoCentryx, supplementing an already strong team with growing expertise in drug discovery, development, and commercial execution.” About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokin...